PREVENTION OF CHEMOTHERAPY-INDUCED NEUTROPENIA USING G-CSF WITH VACOP-B - A CASE-REPORT

被引：1

作者：

ANGLIN, P ^{[1
]}

STRAUSS, BA ^{[1
]}

BRANDWEIN, JM ^{[1
]}

机构：

[1] UNIV TORONTO,ST MICHAELS HOSP,DIV HEMATOL,TORONTO M5B 1W8,ON,CANADA

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 11卷 / 5-6期

关键词：

G-CSF; HEMATOPOIETIC GROWTH FACTORS; NEUTROPENIA; NON-HODGKINS LYMPHOMA; CHEMOTHERAPY;

D O I：

10.3109/10428199309067942

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hematopoietic growth factors, including granulocyte colony-stimulating factor (G-CSF), are being increasingly used to prevent chemotherapy-induced neutropenia. We report a patient with aggressive non-Hodgkin's lymphoma who was successfully supported with G-CSF through a weekly VACOP-B chemotherapy regimen. The patient had become severely neutropenic at week 3, requiring a one-week delay. For the remainder of the treatment, G-CSF at a dose of 4 mu g/kg/day was administered daily over 4 days after week 4, then over 3 days thereafter, beginning the day after the non-myelosuppressive weeks (vincristine/bleomycin). A total of 5 such G-CSF courses were given, with no further neutropenia despite administration of full chemotherapy doses on schedule. This case suggests that, at least with the VACOP-B regimen, chemotherapy-induced neutropenia can be prevented using much lower quantities of G-CSF than has been reported using other regimens.

引用

页码：469 / 472

页数：4

共 17 条

[1]

DeVita V.T., Hubbard S.M., Young R.C., Et al., The role of chemotherapy in diffuse aggressive lymphomas, Sem. Hematol., 25, pp. 2-10, (1988)

[2]

Dodwell D.J., Gumey H., Thatcher N., Dose toxicity in cancer chemotherapy, Br. J. Cancer, 61, pp. 784-794

[3]

Frei E.F., Canellos G.P., Dose: A critical factor in cancer chemotherapy, Am. J. MEd., 69, pp. 585-595, (1980)

[4]

Metcalf D., The colony-stimulating factors: discovery, development and clinical applications, Cancer, 65, pp. 2185-2195, (1990)

[5]

Groopman J.E., Molina J.M., Scadden D.T., Haematopoietic growth factors: Biology and clinical applications, N. Eng. J. Med., 321, pp. 1449-1459, (1989)

[6]

Souza L.M., Boone T.C., Gabrilove J., Et al., Recombinant human granulocyte colony-stimulating factor: effects on normal and leukaemic myeloid cells, Science, 232, pp. 61-65, (1986)

[7]

Hemato-poietic Growth Factors in Clinical Applications, (1990)

[8]

Lieschke G., Burgess A., Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor, N. Eng. J. Med., 327, 28-35, pp. 99-106, (1992)

[9]

Crawford J., Ozer H., Stoller R., Et al., Reduction by granulocyte colony-stimulating factor of fever and neutro-penia induced by chemotherapy in patients with small cell lung cancer, N. Eng. J. Med., 325, pp. 164-170, (1991)

[10]

Gabrilove J., Jakubowski A., Scher H., Et al., The effect of granulocyte colony stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium, N. Eng. J. Med., 338, pp. 1414-1422, (1988)

← 1 2 →